Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,067 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00021255 | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer | completed | Phase 3 | 3,222 | SanofiINDUSTRY | 42 | Nov 15, 2016 | clinicaltrials |
| NCT00760877 | Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR) | completed | Phase 3 | 207 | Novartis PharmaceuticalsINDUSTRY | 6 |
| Nov 8, 2016 |
| clinicaltrials |
| NCT00661102 | A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine). | completed | Phase 3 | 598 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT00806923 | A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 1,044 | Hoffmann-La RocheINDUSTRY | 20 | Nov 2, 2016 | clinicaltrials |
| NCT02563054 | A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer | completed | Phase 3 | 316 | Hoffmann-La RocheINDUSTRY | 14 | Nov 2, 2016 | clinicaltrials |
| NCT00829166 | A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer(EMILIA) | completed | Phase 3 | 991 | Hoffmann-La RocheINDUSTRY | 27 | Oct 31, 2016 | clinicaltrials |
| NCT00744497 | Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer(READY) | completed | Phase 3 | 1,930 | Bristol-Myers SquibbINDUSTRY | 25 | Oct 17, 2016 | clinicaltrials |
| NCT00858871 | First Line Hepato Cellular Carcinoma (HCC)(BRISK FL) | completed | Phase 3 | 1,714 | Bristol-Myers SquibbINDUSTRY | 26 | Oct 17, 2016 | clinicaltrials |
| NCT01419197 | A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy(TH3RESA) | completed | Phase 3 | 602 | Hoffmann-La RocheINDUSTRY | 22 | Oct 12, 2016 | clinicaltrials |
| NCT02574780 | Lymphedema Upper Limb of Breast Cancer Through Muscle Strengthening Associated With Complex Physical Therapy(LTP) | completed | Phase 2 / Phase 3 | 42 | Federal University of São PauloOTHER | 1 | Oct 10, 2016 | clinicaltrials |
| NCT00069095 | A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer | completed | Phase 3 | 2,035 | Hoffmann-La RocheINDUSTRY | 33 | Oct 6, 2016 | clinicaltrials |
| NCT00312377 | ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer(ZODIAC) | completed | Phase 3 | 1,690 | Genzyme, a Sanofi CompanyINDUSTRY | 25 | Sep 30, 2016 | clinicaltrials |
| NCT00861614 | Study of Immunotherapy to Treat Advanced Prostate Cancer | completed | Phase 3 | 988 | Bristol-Myers SquibbINDUSTRY | 27 | Sep 30, 2016 | clinicaltrials |
| NCT00056407 | "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk(REDUCE) | completed | Phase 3 | 8,231 | GlaxoSmithKlineINDUSTRY | 42 | Sep 23, 2016 | clinicaltrials |
| NCT00022516 | Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer(22-00) | completed | Phase 3 | 1,086 | ETOP IBCSG Partners FoundationNETWORK | 11 | Sep 16, 2016 | clinicaltrials |
| NCT01343277 | A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma | completed | Phase 3 | 579 | Janssen Research & Development, LLCINDUSTRY | 4 | Aug 26, 2016 | clinicaltrials |
| NCT00123474 | Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML | completed | Phase 3 | 724 | Bristol-Myers SquibbINDUSTRY | 31 | Aug 25, 2016 | clinicaltrials |
| NCT01620138 | Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas | completed | Phase 2 / Phase 3 | 21 | Universidade Federal do Rio de JaneiroOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT01057810 | Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | completed | Phase 3 | 837 | Bristol-Myers SquibbINDUSTRY | 24 | Aug 18, 2016 | clinicaltrials |
| NCT01460472 | Immunotherapy With Racotumomab in Advanced Lung Cancer | unknown | Phase 3 | 1,082 | Recombio SLINDUSTRY | 7 | Jul 29, 2016 | clinicaltrials |
| NCT00519285 | Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer(VENICE) | completed | Phase 3 | 1,224 | SanofiINDUSTRY | 31 | Jul 22, 2016 | clinicaltrials |
| NCT01034163 | A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma (HL)(PATH) | completed | Phase 3 | 41 | Novartis PharmaceuticalsINDUSTRY | 14 | Jul 7, 2016 | clinicaltrials |
| NCT00686959 | Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer(PROCLAIM) | completed | Phase 3 | 598 | Eli Lilly and CompanyINDUSTRY | 19 | Jun 28, 2016 | clinicaltrials |
| NCT00009737 | A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer | completed | Phase 3 | 1,987 | Hoffmann-La RocheINDUSTRY | 14 | Jun 22, 2016 | clinicaltrials |
| NCT01494506 | Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer(NAPOLI-1) | completed | Phase 3 | 417 | Merrimack PharmaceuticalsINDUSTRY | 15 | Jun 17, 2016 | clinicaltrials |
| NCT00785785 | A Study of Nilotinib Versus Imatinib in GIST Patients(ENESTg1) | completed | Phase 3 | 644 | Novartis PharmaceuticalsINDUSTRY | 35 | Jun 16, 2016 | clinicaltrials |
| NCT01239732 | A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer | completed | Phase 3 | 1,021 | Hoffmann-La RocheINDUSTRY | 37 | Jun 10, 2016 | clinicaltrials |
| NCT00417209 | Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen(PAPRIKA) | completed | Phase 3 | 408 | SanofiINDUSTRY | 21 | Jun 3, 2016 | clinicaltrials |
| NCT00400478 | A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13 | completed | Phase 3 | 683 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 26 | May 26, 2016 | clinicaltrials |
| NCT00602745 | S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen(S-1 Pancreas) | terminated | Phase 3 | 61 | SanofiINDUSTRY | 17 | May 26, 2016 | clinicaltrials |
| NCT01350804 | Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)(NURTURE 1) | completed | Phase 3 | 551 | Novartis PharmaceuticalsINDUSTRY | 15 | May 23, 2016 | clinicaltrials |
| NCT00625664 | Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer(CILAB) | completed | Phase 3 | 337 | SanofiINDUSTRY | 19 | May 5, 2016 | clinicaltrials |
| NCT00305188 | Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy. | completed | Phase 3 | 879 | SanofiINDUSTRY | 13 | May 4, 2016 | clinicaltrials |
| NCT00631371 | Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects(INTORACT) | completed | Phase 3 | 791 | PfizerINDUSTRY | 30 | Apr 27, 2016 | clinicaltrials |
| NCT00257608 | A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS) | completed | Phase 3 | 1,145 | Genentech, Inc.INDUSTRY | 17 | Apr 18, 2016 | clinicaltrials |
| NCT01254188 | Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients(ENESTxtnd) | completed | Phase 3 | 421 | Novartis PharmaceuticalsINDUSTRY | 19 | Mar 3, 2016 | clinicaltrials |
| NCT01250379 | A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA) | completed | Phase 3 | 494 | Hoffmann-La RocheINDUSTRY | 13 | Feb 11, 2016 | clinicaltrials |
| NCT01697072 | First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma(RILOMET-1) | terminated | Phase 3 | 609 | AmgenINDUSTRY | 27 | Feb 9, 2016 | clinicaltrials |
| NCT00554229 | A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases(ENTHUSE M1) | completed | Phase 3 | 896 | AstraZenecaINDUSTRY | 31 | Feb 8, 2016 | clinicaltrials |
| NCT00334282 | Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma | completed | Phase 3 | 435 | GlaxoSmithKlineINDUSTRY | 25 | Feb 5, 2016 | clinicaltrials |
| NCT00333775 | A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer | completed | Phase 3 | 736 | Hoffmann-La RocheINDUSTRY | 24 | Jan 27, 2016 | clinicaltrials |
| NCT01140347 | A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib(REACH) | completed | Phase 3 | 565 | Eli Lilly and CompanyINDUSTRY | 27 | Dec 28, 2015 | clinicaltrials |
| NCT00412776 | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer | terminated | Phase 2 / Phase 3 | 165 | Sesen Bio, Inc.INDUSTRY | 18 | Dec 23, 2015 | clinicaltrials |
| NCT00699517 | A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies | completed | Phase 3 | 355 | SanofiINDUSTRY | 10 | Dec 21, 2015 | clinicaltrials |
| NCT01223027 | Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma | completed | Phase 3 | 564 | Novartis PharmaceuticalsINDUSTRY | 27 | Dec 7, 2015 | clinicaltrials |
| NCT00409188 | Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)(START) | completed | Phase 3 | 1,513 | EMD SeronoINDUSTRY | 33 | Nov 20, 2015 | clinicaltrials |
| NCT00802841 | Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib(LASOR) | completed | Phase 3 | 191 | Novartis PharmaceuticalsINDUSTRY | 12 | Nov 16, 2015 | clinicaltrials |
| NCT01234311 | A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer | completed | Phase 3 | 1,245 | Active Biotech ABINDUSTRY | 37 | Oct 21, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials